Haleos Labs Limited

Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 1,426.5, sellers were still queuing — but there were no buyers willing to take the other side. Haleos Labs Limited locked at its lower circuit of 9.79% on 1 Jun 2026, with unfilled sell orders and a frozen price.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. Despite the company’s shares outperforming the broader market indices over multiple time horizons, key profitability and revenue metrics have taken a marked downturn, signalling challenges ahead for investors.

Haleos Labs Limited reported a consolidated net profit of ₹0.44 crores for Q4 FY26, representing a dramatic decline of 93.35% quarter-on-quarter and 85.19% year-on-year, raising serious questions about the pharmaceutical company's operational efficiency and profitability trajectory. The micro-cap company, with a market capitalisation of ₹517.00 crores, saw its shares trade at ₹1,689.95 on May 29, 2026, up 3.68% from the previous close, suggesting investors may be looking past the disappointing quarterly performance towards potential recovery prospects.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 28 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Despite some bearish signals on the weekly and monthly RSI, the stock’s overall technical indicators suggest a strengthening upward trajectory, supported by robust moving averages and bullish MACD readings. This nuanced technical landscape offers investors a complex but promising outlook on the stock’s near-term potential.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable shift in price momentum and technical indicators, prompting an upgrade in its Mojo Grade from Sell to Hold. The stock’s recent performance, buoyed by bullish signals on multiple timeframes, contrasts with some cautionary monthly indicators, reflecting a nuanced outlook for investors.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with an up-to-date view of the company's performance and outlook.

Surging past its previous peaks, Haleos Labs Limited touched a new 52-week high of Rs 1738.35 on 11 May 2026, marking a significant milestone amid a challenging broader market environment. The stock’s recent momentum is underpinned by a confluence of bullish technical indicators, signalling robust price strength despite the Sensex’s ongoing weakness.

With a decisive break above Rs 1642.5 on 8 May 2026, Haleos Labs Limited has reached a fresh 52-week high, extending its impressive 26.8% gain over the past year against a declining Sensex. This milestone underscores the stock’s robust technical momentum amid a mixed broader market backdrop.

With a decisive surge to Rs 1638.15 on 7 May 2026, Haleos Labs Limited has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally comes amid a backdrop of strong technical signals and sustained upward movement across multiple timeframes, underscoring the stock's robust price action despite a mixed broader market environment.

Surging past its previous peaks, Haleos Labs Limited touched a new 52-week high of Rs 1620 on 6 May 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and outperformance relative to its sector and the broader market.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 06 May 2026, providing investors with the latest insights into the company’s performance and outlook.

With a decisive surge to Rs 1540 on 29 Apr 2026, Haleos Labs Limited has marked a fresh 52-week high, reflecting robust momentum across multiple technical indicators and outperforming its sector peers.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 13 April 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling a cautious but positive outlook for investors.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 8 April 2026. This change reflects a deterioration in technical indicators despite the company’s positive quarterly financial performance and long-term market-beating returns. Investors are advised to weigh the mixed signals from quality, valuation, financial trends, and technicals before making decisions.

Haleos Labs Limited has seen its investment rating upgraded from Sell to Hold as of 2 April 2026, reflecting a notable shift in technical indicators and valuation metrics. Despite some lingering concerns over long-term fundamentals, the company’s recent financial performance and market behaviour have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.